QLS-1304

N/A

Report date: 2025/11/20 20:00:05
NME

Base Information

Drug NameQLS-1304
Drug Alias NameQLS1304QLS-1304
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone acetyltransferase KAT6A inhibitorsHistone acetyltransferase KAT6B inhibitors
TargetsHistone acetyltransferase KAT6AHistone acetyltransferase KAT6B
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursBreast Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A